Document Detail

HER-2/neu as a target for cancer vaccines.
MedLine Citation:
PMID:  20635929     Owner:  NLM     Status:  MEDLINE    
A novel modality toward the treatment of HER-2/neu-positive malignancies, mostly including breast and, more recently prostate carcinomas, has been the use of vaccines targeting HER-2/neu extracellular and intracellular domains. HER-2/neu-specific vaccines have been demonstrated to generate durable T-cell anti-HER-2/neu immunity when tested in Phase I and II clinical trials with no significant toxicity or autoimmunity directed against normal tissues. Targeting of HER-2/neu in active immunotherapy may involve peptide and DNA vaccines. Moreover, active anti-HER-2/neu immunization could facilitate the ex vivo expansion of HER-2/neu-specific T cells for use in adoptive immunotherapy for the treatment of established metastatic disease. In addition, early data from trials examining the potential use of HER-2/neu-based vaccines in the adjuvant setting to prevent the relapse of breast cancer in high-risk patients have shown promising results. Future approaches include multiepitope preventive vaccines and combinatorial treatments for generating the most efficient protective anti-tumor immunity.
Constantin N Baxevanis; Ioannis F Voutsas; Angelos D Gritzapis; Sonia A Perez; Michael Papamichail
Related Documents :
19335279 - Dcvax-brain and dc vaccines in the treatment of gbm.
12014629 - A dendritic cell vaccine induces protective immunity to intracranial growth of glioma.
9789739 - Dendritic cell responsiveness to stimulation with influenza vaccine is unimpaired in ol...
8873049 - Allogeneic murine melanoma cell vaccine: a model for the development of human allogenei...
18294279 - Co-administration of carcinoembryonic antigen and hiv tat fusion protein with cpg-oligo...
175929 - Vaccination of nonhuman primates with killed oncogenic herpesviruses.
20576729 - Determining the optimal pneumococcal vaccination strategy for adults: is there a role f...
21718739 - An immunological comparison between lipidated and non-lipidated multivalent hiv-1 pepti...
18656409 - Mosquito-based transmission blocking vaccines for interrupting plasmodium development.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Immunotherapy     Volume:  2     ISSN:  1750-7448     ISO Abbreviation:  Immunotherapy     Publication Date:  2010 Mar 
Date Detail:
Created Date:  2010-07-19     Completed Date:  2010-11-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101485158     Medline TA:  Immunotherapy     Country:  England    
Other Details:
Languages:  eng     Pagination:  213-26     Citation Subset:  IM    
Cancer Immunology & Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antigens, Neoplasm / immunology*
Cancer Vaccines / adverse effects,  immunology*
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Genes, erbB-2
Immunotherapy, Active*
Immunotherapy, Adoptive
Mice, Inbred BALB C
Neoplasms / immunology,  therapy
Peptide Fragments / administration & dosage,  immunology
Receptor, erbB-2 / immunology*
T-Lymphocytes, Cytotoxic / immunology,  transplantation
T-Lymphocytes, Helper-Inducer / immunology
Vaccines, DNA / therapeutic use
Vaccines, Subunit / therapeutic use
Vaccines, Synthetic / immunology,  therapeutic use
Reg. No./Substance:
0/Antigens, Neoplasm; 0/Cancer Vaccines; 0/HER-2 peptide E75 (369-377), human; 0/Peptide Fragments; 0/Vaccines, DNA; 0/Vaccines, Subunit; 0/Vaccines, Synthetic; EC protein, human; EC, erbB-2

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Immune response against tumor antigens expressed on human cancer stem-like cells/tumor-initiating ce...
Next Document:  Immunotherapy of chronic myeloid leukemia: present state and future prospects.